Clostridioides difficile infection: a changing treatment paradigm
Clostridioides difficile infection (CDI) poses a persistent challenge in healthcare, with substantial morbidity and mortality implications. This comprehensive review explores current CDI management, emphasising guidelines from IDSA, SHEA, and ESCMID. Additionally, this study spotlights recent drug d...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Termedia Publishing House
2024-03-01
|
| Series: | Gastroenterology Review |
| Subjects: | |
| Online Access: | https://www.termedia.pl/Clostridioides-difficile-infection-a-changing-treatment-paradigm,41,52631,1,1.html |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841548279605624832 |
|---|---|
| author | Yousif Al Naser Marriam AlGashami Layth Aljashaami |
| author_facet | Yousif Al Naser Marriam AlGashami Layth Aljashaami |
| author_sort | Yousif Al Naser |
| collection | DOAJ |
| description | Clostridioides difficile infection (CDI) poses a persistent challenge in healthcare, with substantial morbidity and mortality implications. This comprehensive review explores current CDI management, emphasising guidelines from IDSA, SHEA, and ESCMID. Additionally, this study spotlights recent drug developments that have the potential to reshape CDI treatment paradigms. Within the current treatment landscape, fidaxomicin, vancomycin, bezlotoxumab, and faecal microbiota transplantation offer varied options, each with its unique strengths and limitations. Fidaxomicin, effective yet resource-constrained, presents a dilemma, with vancomycin emerging as a pragmatic alternative. Bezlotoxumab, though augmenting antibiotics, grapples with cost and safety concerns. Meanwhile, faecal microbiota transplantation, highly efficacious, confronts evolving safety considerations. The horizon of CDI treatment also features promising therapies such as SER-109 and Rebyota, epitomising the evolving paradigm. As CDI management advances, the critical role of standardised microbiome restoration therapies becomes evident, ensuring long-term safety and diversifying treatment strategies. |
| format | Article |
| id | doaj-art-07eb7dea7aa44aa4a4dd787bb82a5412 |
| institution | Kabale University |
| issn | 1895-5770 1897-4317 |
| language | English |
| publishDate | 2024-03-01 |
| publisher | Termedia Publishing House |
| record_format | Article |
| series | Gastroenterology Review |
| spelling | doaj-art-07eb7dea7aa44aa4a4dd787bb82a54122025-01-10T14:06:16ZengTermedia Publishing HouseGastroenterology Review1895-57701897-43172024-03-011911510.5114/pg.2024.13623752631Clostridioides difficile infection: a changing treatment paradigmYousif Al NaserMarriam AlGashamiLayth AljashaamiClostridioides difficile infection (CDI) poses a persistent challenge in healthcare, with substantial morbidity and mortality implications. This comprehensive review explores current CDI management, emphasising guidelines from IDSA, SHEA, and ESCMID. Additionally, this study spotlights recent drug developments that have the potential to reshape CDI treatment paradigms. Within the current treatment landscape, fidaxomicin, vancomycin, bezlotoxumab, and faecal microbiota transplantation offer varied options, each with its unique strengths and limitations. Fidaxomicin, effective yet resource-constrained, presents a dilemma, with vancomycin emerging as a pragmatic alternative. Bezlotoxumab, though augmenting antibiotics, grapples with cost and safety concerns. Meanwhile, faecal microbiota transplantation, highly efficacious, confronts evolving safety considerations. The horizon of CDI treatment also features promising therapies such as SER-109 and Rebyota, epitomising the evolving paradigm. As CDI management advances, the critical role of standardised microbiome restoration therapies becomes evident, ensuring long-term safety and diversifying treatment strategies.https://www.termedia.pl/Clostridioides-difficile-infection-a-changing-treatment-paradigm,41,52631,1,1.htmlclostridioides difficile infection microbiota faecal transplant drug development. |
| spellingShingle | Yousif Al Naser Marriam AlGashami Layth Aljashaami Clostridioides difficile infection: a changing treatment paradigm Gastroenterology Review clostridioides difficile infection microbiota faecal transplant drug development. |
| title | Clostridioides difficile infection: a changing treatment paradigm |
| title_full | Clostridioides difficile infection: a changing treatment paradigm |
| title_fullStr | Clostridioides difficile infection: a changing treatment paradigm |
| title_full_unstemmed | Clostridioides difficile infection: a changing treatment paradigm |
| title_short | Clostridioides difficile infection: a changing treatment paradigm |
| title_sort | clostridioides difficile infection a changing treatment paradigm |
| topic | clostridioides difficile infection microbiota faecal transplant drug development. |
| url | https://www.termedia.pl/Clostridioides-difficile-infection-a-changing-treatment-paradigm,41,52631,1,1.html |
| work_keys_str_mv | AT yousifalnaser clostridioidesdifficileinfectionachangingtreatmentparadigm AT marriamalgashami clostridioidesdifficileinfectionachangingtreatmentparadigm AT laythaljashaami clostridioidesdifficileinfectionachangingtreatmentparadigm |